1. Home
  2. HOMB vs ERAS Comparison

HOMB vs ERAS Comparison

Compare HOMB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

HOLD

Current Price

$28.00

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$17.03

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOMB
ERAS
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.5B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
HOMB
ERAS
Price
$28.00
$17.03
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$32.40
$12.08
AVG Volume (30 Days)
1.2M
4.8M
Earning Date
04-15-2026
05-12-2026
Dividend Yield
2.94%
N/A
EPS Growth
19.90
36.23
EPS
2.41
N/A
Revenue
N/A
N/A
Revenue This Year
$10.99
N/A
Revenue Next Year
$5.14
N/A
P/E Ratio
$11.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.98
$1.06
52 Week High
$30.83
$18.20

Technical Indicators

Market Signals
Indicator
HOMB
ERAS
Relative Strength Index (RSI) 58.67 62.62
Support Level $27.68 $1.57
Resistance Level $28.74 N/A
Average True Range (ATR) 0.51 1.03
MACD 0.27 0.07
Stochastic Oscillator 72.86 73.62

Price Performance

Historical Comparison
HOMB
ERAS

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: